Skip to content

Closed-loop DBS in Parkinson's Disease

Safety and Effectiveness of Closed-loop DBS in Parkinson's Disease: A Long-term Follow-up Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06012461
Enrollment
10
Registered
2023-08-25
Start date
2023-06-30
Completion date
2025-12-30
Last updated
2023-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Keywords

Parkinson Disease, Deep Brain Stimulation, Closed-loop DBS

Brief summary

Closed-loop DBS is an emerging neuromodulation pattern in Parkinson's disease with dyanmic adjustment of stimulation parameters to patients' disease fluctuations and state of activity. The purpose of this study is to verify the long-term safety and effectiveness of closed-loop DBS. Through comparing with open-loop DBS, the study also determine whether closed-loop DBS is more effective than conventional open-loop DBS on PD treatment.

Interventions

OTHERClosed-loop DBS stimulation for 24 hours

Continuous closed-loop modulation for 24 hours

OTHEROpen-loop DBS stimulation for 24 hours

Continuous open-loop modulation for 24 hours

OTHERClosed-loop DBS stimulation for 72 hours

Continuous closed-loop modulation for 72 hours

OTHEROpen-loop DBS stimulation for 72 hours

Continuous open-loop modulation for 72 hours

Sponsors

National Engineering Research Center of Neuromodulation, Tsinghua University
CollaboratorUNKNOWN
Beijing Tiantan Hospital
CollaboratorOTHER
Peking Union Medical College Hospital
CollaboratorOTHER
Beijing Pins Medical Co., Ltd
CollaboratorINDUSTRY
Tsinghua University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Diagnosis of primary Parkinson's disease: Diagnosis of primary Parkinson's disease should meet the diagnostic criteria outlined in the Diagnosis Standards for Parkinson's Disease in China published in 2016 or the diagnostic criteria for primary Parkinson's disease by the International Parkinson and Movement Disorder Society (MDS) published in 2015. 2. Good response to levodopa combination therapy. 3. Significant reduction in drug efficacy or significant impact on the patient's quality of life due to prominent motor complications. 4. Intolerable adverse reactions to medication affecting its efficacy. 5. Presence of uncontrollable tremors despite medication.

Exclusion criteria

1. Patients who have undergone pallidotomy or other brain surgeries. 2. Patients with secondary Parkinson syndromes or Parkinson plus syndromes. 3. Patients with concurrent central nervous system and peripheral nervous system diseases. 4. Patients with severe systemic diseases, unstable vital signs, or those who cannot tolerate clinical assessments. 5. Patients with severe psychiatric disorders. 6. Patients who are unable to provide informed consent due to cognitive or communication impairments or those who refuse to sign the informed consent form.

Design outcomes

Primary

MeasureTime frameDescription
Sleep Structure Evaluation1-3 nightsUsing polysomnography evaluation (sleep efficiency,N1/N2/N3/REM/Wake after sleep onset duration and percentage,arousal index) and subjuective sleep quality rating scale to evaluate the sleep improvement under both closed-loop DBS and open-loop DBS condition
Movement disorders evaluation1-3 daysUsing MDS-UPDRS III rating scale (0-132, the higher score means a worse outcome) and Rush dyskinesia rating scale (0-12, the higher score means a worse outcome) combined with IMU to evaluate the motor function improvement under both closed-loop DBS and open-loop DBS condition
Diary Outcomes in Parkinson's Disease1-3daysUsing SCOPA-DC (0-87, the higher score means a worse outcome) to evaluate the diary outcomes under both closed-loop DBS and open-loop DBS condition

Secondary

MeasureTime frameDescription
Total Electrical Energy Delivered to patients1-3daysTo evaluate the energy changes in closed-loop DBS and open-loop DBS modualtion
Safety (Stimulation-related AEs) and Subjective Satisfactory1-3daysNumber of modulation related Adverse Events or abnormal vital signs.

Other

MeasureTime frameDescription
Neurophysiological changes of STN-LFP in daytime and sleepat 3,6,9,12,15 months compared to baselineChanges of the power and entropy features of delta, theta, alpha, beta and gamma oscillations
Functional connectivity changes during long-term DBS modulationat 3,6,9,12,15 months compared to baselineChanges of subcortical and cortical functional connectivity

Countries

China

Contacts

Primary ContactWeizhi Pan, B.S.
neln@mail.tsinghua.edu.cn+86-010-62796172

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026